Frontotemporal Lobar degeneration (FTLD) manifests clinically with progressive behavioral and/or language deficits. Subtypes of FTLD are classified neuropathologically by the protein composition of cellular inclusion bodies. The most common neuropathological correlates of FTLD have TAR DNA binding protein (TDP-43) inclusions (FTLD-TDP) or tau inclusions (FTLD-tau). FTLD is frequently familial and can occur as an autosomal dominantly inherited disorder. Genes with mutations causing FTLD include /W/APT (encodes tau) and GRN (encodes progranulin) among others, each of which is associated with a specific FTLD pathological subtype: GRN mutations with FTLD-TDP and MAPT mutations with FTLD-tau. Studying the genetics of FTLD can help elucidate its etiology and pathophysiology and provide targets for therapy as well as identify risk factors that modify disease risk or phenotype. To enable genetic studies of FTLD the Genetics Core, as an integral part of this Program Project Grant, will collect and bank DNA from Clinical Core B subjects with FTLD and autopsy brains characterized in the Neuropathology Core as well as control samples. For participating individuals, a study coordinator trained as a certified genetic counselor will provide genetic education to foster a better understanding of the research and to obtain informed consent. Banked DNA will be used for genetic analysis by the Core itself, as well as by Project 1, and other collaborators within and outside of UPenn. Genetic analysis of FTLD associated genes will be performed by the Core and in collaboration with Project 1. Genotype data will enable clinical, pathologic and genetic correlations with data from Projects 1 and 3 and the Clinical and Neuropathology Cores with statistical analysis by the Biostatistics and Data Management Core. Projects 2 and 4 will use genotype data for case selection for analysis. Finally, the Genetics Core will coordinate with the Hosp. of the Univ. of Penn Molecular Pathology Lab to make CLIA-certified genetic testing available. To this end, the Core will identify new genetic tests which are ready for translation into clinical tests and assist with validation by providing primer sequences, protocols, and samples

Public Health Relevance

The Studies proposed in this Core taken together with the complementary activities in the other Cores and Projects in this PPG will lead to improved understanding of the genetics of FTLD and related neurodegenerative disorders and will contrilDute samples to collaborafive projects advancing the field as a whole.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG017586-13
Application #
8444443
Study Section
Special Emphasis Panel (ZAG1-ZIJ-4)
Project Start
Project End
Budget Start
2013-03-01
Budget End
2014-02-28
Support Year
13
Fiscal Year
2013
Total Cost
$171,278
Indirect Cost
$64,229
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Sanchez-Contreras, Monica Y; Kouri, Naomi; Cook, Casey N et al. (2018) Replication of progressive supranuclear palsy genome-wide association study identifies SLCO1A2 and DUSP10 as new susceptibility loci. Mol Neurodegener 13:37
Robinson, John L; Corrada, Maria M; Kovacs, Gabor G et al. (2018) Non-Alzheimer's contributions to dementia and cognitive resilience in The 90+ Study. Acta Neuropathol :
Brettschneider, Johannes; Suh, EunRan; Robinson, John L et al. (2018) Converging Patterns of ?-Synuclein Pathology in Multiple System Atrophy. J Neuropathol Exp Neurol 77:1005-1016
Suh, EunRan; Grando, Kaitlyn; Van Deerlin, Vivianna M (2018) Validation of a Long-Read PCR Assay for Sensitive Detection and Sizing of C9orf72 Hexanucleotide Repeat Expansions. J Mol Diagn 20:871-882
Zee, Jarcy; Xie, Sharon X (2018) The Kaplan-Meier Method for Estimating and Comparing Proportions in a Randomized Controlled Trial with Dropouts. Biostat Epidemiol 2:23-33
Oukoloff, Killian; Kovalevich, Jane; Cornec, Anne-Sophie et al. (2018) Design, synthesis and evaluation of photoactivatable derivatives of microtubule (MT)-active [1,2,4]triazolo[1,5-a]pyrimidines. Bioorg Med Chem Lett 28:2180-2183
Phillips, Jeffrey S; Das, Sandhitsu R; McMillan, Corey T et al. (2018) Tau PET imaging predicts cognition in atypical variants of Alzheimer's disease. Hum Brain Mapp 39:691-708
Smith, Kara M; Ash, Sharon; Xie, Sharon X et al. (2018) Evaluation of Linguistic Markers of Word-Finding Difficulty and Cognition in Parkinson's Disease. J Speech Lang Hear Res 61:1691-1699
Deming, Yuetiva; Dumitrescu, Logan; Barnes, Lisa L et al. (2018) Sex-specific genetic predictors of Alzheimer's disease biomarkers. Acta Neuropathol 136:857-872
Gangishetti, Umesh; Christina Howell, J; Perrin, Richard J et al. (2018) Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease. Alzheimers Res Ther 10:98

Showing the most recent 10 out of 593 publications